Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice

Changes to innate cells, such as macrophages and myeloid-derived suppressor cells (MDSCs), during aging in healthy or tumor-bearing hosts are not well understood. We compared macrophage subpopulations and MDSCs from healthy young (6–8 weeks) C57BL/6J mice to those from healthy geriatric (24–28 month...

Full description

Bibliographic Details
Main Authors: Jackaman, Connie, Radley-Crabb, Hannah, Soffe, Z., Shavlakadze, T., Grounds, M., Nelson, Delia
Format: Journal Article
Published: Wiley-Blackwell 2013
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/44664
_version_ 1848757066441687040
author Jackaman, Connie
Radley-Crabb, Hannah
Soffe, Z.
Shavlakadze, T.
Grounds, M.
Nelson, Delia
author_facet Jackaman, Connie
Radley-Crabb, Hannah
Soffe, Z.
Shavlakadze, T.
Grounds, M.
Nelson, Delia
author_sort Jackaman, Connie
building Curtin Institutional Repository
collection Online Access
description Changes to innate cells, such as macrophages and myeloid-derived suppressor cells (MDSCs), during aging in healthy or tumor-bearing hosts are not well understood. We compared macrophage subpopulations and MDSCs from healthy young (6–8 weeks) C57BL/6J mice to those from healthy geriatric (24–28 months) mice. Spleens, lymph nodes, and bone marrow of geriatric hosts contained significantly more M2 macrophages and MDSCs than their younger counterparts. Peritoneal macrophages from geriatric, but not young, mice co-expressed CD40 and CX3CR1 that are usually mutually exclusively expressed by M1 or M2 macrophages. Nonetheless, macrophages from geriatric mice responded to M1 or M2 stimuli similarly to macrophages from young mice, although they secreted higher levels of TGF-β in response to IL-4. We mimicked conditions that may occur within tumors by exposing macrophages from young vs. geriatric mice to mesothelioma or lung carcinoma tumor cell–derived supernatants. While both supernatants skewed macrophages toward the M2-phenotype regardless of age, only geriatric-derived macrophages produced IL-4, suggesting a more immunosuppressive tumor microenvironment will be established in the elderly. Both geriatric- and young-derived macrophages induced allogeneic T-cell proliferation, regardless of the stimuli used, including tumor supernatant. However, only macrophages from young mice induced T-cell IFN-γ production. We examined the potential of an IL-2/agonist anti-CD40 antibody immunotherapy that eradicates large tumors in young hosts to activate macrophages from geriatric mice. IL-2-/CD40-activated macrophages rescued T-cell production of IFN-γ in geriatric mice. Therefore, targeting macrophages with IL-2/anti-CD40 antibody may improve innate and T-cell immunity in aging hosts.
first_indexed 2025-11-14T09:22:11Z
format Journal Article
id curtin-20.500.11937-44664
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:22:11Z
publishDate 2013
publisher Wiley-Blackwell
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-446642017-09-13T14:15:05Z Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice Jackaman, Connie Radley-Crabb, Hannah Soffe, Z. Shavlakadze, T. Grounds, M. Nelson, Delia interleukin-2 cancer immunotherapy macrophage CD40 aging Changes to innate cells, such as macrophages and myeloid-derived suppressor cells (MDSCs), during aging in healthy or tumor-bearing hosts are not well understood. We compared macrophage subpopulations and MDSCs from healthy young (6–8 weeks) C57BL/6J mice to those from healthy geriatric (24–28 months) mice. Spleens, lymph nodes, and bone marrow of geriatric hosts contained significantly more M2 macrophages and MDSCs than their younger counterparts. Peritoneal macrophages from geriatric, but not young, mice co-expressed CD40 and CX3CR1 that are usually mutually exclusively expressed by M1 or M2 macrophages. Nonetheless, macrophages from geriatric mice responded to M1 or M2 stimuli similarly to macrophages from young mice, although they secreted higher levels of TGF-β in response to IL-4. We mimicked conditions that may occur within tumors by exposing macrophages from young vs. geriatric mice to mesothelioma or lung carcinoma tumor cell–derived supernatants. While both supernatants skewed macrophages toward the M2-phenotype regardless of age, only geriatric-derived macrophages produced IL-4, suggesting a more immunosuppressive tumor microenvironment will be established in the elderly. Both geriatric- and young-derived macrophages induced allogeneic T-cell proliferation, regardless of the stimuli used, including tumor supernatant. However, only macrophages from young mice induced T-cell IFN-γ production. We examined the potential of an IL-2/agonist anti-CD40 antibody immunotherapy that eradicates large tumors in young hosts to activate macrophages from geriatric mice. IL-2-/CD40-activated macrophages rescued T-cell production of IFN-γ in geriatric mice. Therefore, targeting macrophages with IL-2/anti-CD40 antibody may improve innate and T-cell immunity in aging hosts. 2013 Journal Article http://hdl.handle.net/20.500.11937/44664 10.1111/acel.12062 Wiley-Blackwell unknown
spellingShingle interleukin-2
cancer immunotherapy
macrophage
CD40
aging
Jackaman, Connie
Radley-Crabb, Hannah
Soffe, Z.
Shavlakadze, T.
Grounds, M.
Nelson, Delia
Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title_full Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title_fullStr Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title_full_unstemmed Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title_short Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice
title_sort targeting macrophages rescues age-related immune deficiencies in c57bl/6j geriatric mice
topic interleukin-2
cancer immunotherapy
macrophage
CD40
aging
url http://hdl.handle.net/20.500.11937/44664